| Literature DB >> 29950665 |
Héloïse Proquin1, Marlon J Jetten2, Marloes C M Jonkhout2, Luis Guillermo Garduño-Balderas3, Jacob J Briedé2, Theo M de Kok2, Henk van Loveren2, Yolanda I Chirino3,4.
Abstract
Titanium dioxide as a food additive (E171) has been demonstrated to facilitate growth of chemically induced colorectal tumours in vivo and induce transcriptomic changes suggestive of an immune system impairment and cancer development. The present study aimed to investigate the molecular mechanisms behind the tumour stimulatory effects of E171 in combination with azoxymethane (AOM)/dextran sodium sulphate (DSS) and compare these results to a recent study performed under the same conditions with E171 only. BALB/c mice underwent exposure to 5 mg/kgbw/day of E171 by gavage for 2, 7, 14, and 21 days. Whole genome mRNA microarray analyses on the distal colon were performed. The results show that E171 induced a downregulation of genes involved in the innate and adaptive immune system, suggesting impairment of this system. In addition, over time, signalling genes involved in colorectal cancer and other types of cancers were modulated. In relation to cancer development, effects potentially associated with oxidative stress were observed through modulation of genes related to antioxidant production. E171 affected genes involved in biotransformation of xenobiotics which can form reactive intermediates resulting in toxicological effects. These transcriptomics data reflect the early biological responses induced by E171 which precede tumour formation in an AOM/DSS mouse model.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29950665 PMCID: PMC6021444 DOI: 10.1038/s41598-018-28063-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Summary results of DEG after LIMMA analysis.
| 2 days | 7 days | 14 days | 21 days | |
|---|---|---|---|---|
| |FC|> = 1.5 | 2128 | 5277 | 4671 | 3387 |
| Up-regulated | 1203 | 2567 | 1888 | 616 |
| Down-regulated | 925 | 2710 | 2783 | 2771 |
| p.val < 0.05 | 771 | 5106 | 3622 | 1951 |
| adj.p.val < 0.05 | 0 | 1532 | 246 | 2 |
| |FC| and p.val | 411 | 3506 | 2553 | 1178 |
| |FC| and adj.p.val | 0 | 1390 | 233 | 2 |
Differently Expressed Genes after LIMMA analysis on the microarray data of chemically induced CRC BALB/c mice exposed to 5 mg/kg bw/day of E171. |FC| = Log2 fold change, p.val = p-value, adj.p.val = adjusted p-value.
Figure 1Venn diagram of the overlap (not based on directionality of expression) of DEGs (p < 0.05 and Log2FC > 1.5) at different time points (2, 7, 14, and 21 days) after exposure to E171 in colon of mice. Each colour represents a different day.
Summary table with pathways, number of genes and their direction.
| Days of exposure | Group of pathways | Pathways | q-value | pathway source | Down | Up | Total |
|---|---|---|---|---|---|---|---|
| 2 days | Signal transduction | Olfactory transduction | 5.10E-12 | KEGG | 5 | 26 | 31 |
| Olfactory signalling Pathway | 4.61E-05 | Reactome | 5 | 10 | 15 | ||
| GPCR downstream signalling | 0.0183 | Reactome | 8 | 13 | 21 | ||
| Signalling by GPCR | 0.0347 | Reactome | 8 | 14 | 22 | ||
| 7 days | Signal transduction | Class A/1 (Rhodopsin-like receptors) | 2.42E-03 | Reactome | 45 | 21 | 66 |
| GPCR ligand binding | 3.86E-03 | Reactome | 56 | 23 | 79 | ||
| Peptide ligand-binding receptors | 1.56E-02 | Reactome | 28 | 14 | 42 | ||
| G alpha (s) signalling events | 1.63E-02 | Reactome | 18 | 9 | 27 | ||
| Non-odorant GPCRs | 3.06E-02 | Wikipathways | 36 | 19 | 55 | ||
| Antagonism of Activin by Follistatin | 2.42E-02 | Reactome | 4 | 0 | 4 | ||
| Xenobiotics metabolism | Phase 1 - Functionalization of compounds | 6.41E-04 | Reactome | 6 | 24 | 30 | |
| Biological oxidations | 8.93E-05 | Reactome | 8 | 39 | 47 | ||
| Xenobiotics | 7.40E-04 | Reactome | 1 | 15 | 16 | ||
| Cytochrome P450 - arranged by substrate type | 5.75E-03 | Reactome | 3 | 20 | 23 | ||
| bupropion degradation | 5.75E-03 | MouseCyc | 1 | 13 | 14 | ||
| nicotine degradation III | 7.23E-03 | MouseCyc | 1 | 14 | 15 | ||
| Metabolism of xenobiotics by cytochrome P450 | 7.54E-03 | KEGG | 3 | 23 | 26 | ||
| Drug metabolism - cytochrome P450 | 8.75E-03 | KEGG | 2 | 23 | 25 | ||
| nicotine degradation II | 9.60E-03 | MouseCyc | 2 | 14 | 16 | ||
| Drug metabolism - other enzymes | 2.31E-02 | KEGG | 1 | 16 | 17 | ||
| Metabolism | Nuclear receptors in lipid metabolism and toxicity | 1.04E-02 | Wikipathways | 4 | 9 | 13 | |
| Prostaglandin Synthesis and Regulation | 2.42E-02 | Wikipathways | 10 | 3 | 13 | ||
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | 8.37E-03 | Reactome | 0 | 10 | 10 | ||
| Synthesis of (16–20)-hydroxyeicosatetraenoic acids (HETE) | 3.67E-02 | Reactome | 0 | 10 | 10 | ||
| Ascorbate and aldarate metabolism | 2.53E-02 | KEGG | 0 | 9 | 9 | ||
| Linoleic acid metabolism | 2.24E-02 | KEGG | 2 | 14 | 16 | ||
| Arachidonic acid metabolism | 6.41E-04 | Reactome | 18 | 23 | 41 | ||
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 1.83E-02 | Reactome | 5 | 5 | 10 | ||
| Propanoate metabolism | 4.98E-02 | KEGG | 1 | 11 | 12 | ||
| UDP-N-acetyl-D-glucosamine biosynthesis II | 2.33E-02 | MouseCyc | 1 | 4 | 5 | ||
| Metabolism of proteins | Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 3.86E-03 | Reactome | 5 | 9 | 14 | |
| O-linked glycosylation of mucins | 9.60E-03 | Reactome | 3 | 13 | 16 | ||
| Mucin type O-Glycan biosynthesis | 1.63E-03 | KEGG | 4 | 10 | 14 | ||
| Immune response | Cytokine-cytokine receptor interaction | 5.56E-04 | KEGG | 54 | 13 | 67 | |
| Complement and coagulation cascades | 9.60E-03 | KEGG | 18 | 3 | 21 | ||
| Staphylococcus aureus infection | 4.98E-02 | KEGG | 17 | 0 | 17 | ||
| Cancer signalling | Chemical carcinogenesis | 9.60E-03 | KEGG | 3 | 22 | 25 | |
| FGFR3c ligand binding and activation | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| FGFR3 ligand binding and activation | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| Signalling by activated point mutants of FGFR3 | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| Signalling by FGFR3 mutants | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| FGFR1c ligand binding and activation | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| Signalling by activated point mutants of FGFR1 | 4.98E-02 | Reactome | 2 | 3 | 5 | ||
| Haemostasis | Common Pathway of Fibrin Clot Formation | 4.13E-02 | Reactome | 6 | 1 | 7 | |
| Cell surface interactions at the vascular wall | 2.26E-02 | Reactome | 18 | 8 | 26 | ||
| Extracellular matrix organisation | Extracellular matrix organization | 1.84E-07 | Reactome | 67 | 8 | 75 | |
| Degradation of the extracellular matrix | 3.98E-05 | Reactome | 26 | 5 | 31 | ||
| Activation of Matrix Metalloproteinases | 8.93E-05 | Reactome | 17 | 0 | 17 | ||
| Matrix Metalloproteinases | 3.86E-03 | Wikipathways | 12 | 1 | 13 | ||
| Elastic fibre formation | 2.42E-02 | Reactome | 12 | 1 | 13 | ||
| Collagen formation | 3.69E-02 | Reactome | 21 | 1 | 22 | ||
| Assembly of collagen fibrils and other multimeric structures | 3.83E-02 | Reactome | 11 | 1 | 12 | ||
| Digestive system | Bile secretion | 1.36E-03 | KEGG | 6 | 20 | 26 | |
| Pancreatic secretion | 8.76E-03 | KEGG | 15 | 16 | 31 | ||
| Amino sugar and nucleotide sugar metabolism | 1.03E-02 | KEGG | 3 | 16 | 19 | ||
| Protein digestion and absorption | 9.60E-03 | KEGG | 16 | 12 | 28 | ||
| Mineral absorption | 6.41E-04 | KEGG | 8 | 13 | 21 | ||
| 7 days | Endocrine and metabolic disease | Maturity onset diabetes of the young | 3.86E-03 | KEGG | 0 | 13 | 13 |
| Muscle contraction | Striated Muscle Contraction | 4.07E-04 | Reactome | 15 | 1 | 16 | |
| Muscle contraction | 4.29E-02 | Reactome | 15 | 2 | 17 | ||
| Bone development | Endochondral Ossification | 9.68E-04 | Wikipathways | 20 | 5 | 25 | |
| Endocrine and other factor-regulated calcium reabsorption | 2.17E-02 | KEGG | 5 | 14 | 19 | ||
| Calcium signalling pathway | 2.33E-02 | KEGG | 26 | 20 | 46 | ||
| Transport of molecules | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | 8.76E-03 | Reactome | 12 | 17 | 29 | |
| Ion channel transport | 2.11E-02 | Reactome | 12 | 23 | 35 | ||
| Ion transport by P-type ATPases | 2.26E-02 | Reactome | 7 | 7 | 14 | ||
| Organic cation transport | 4.98E-02 | Reactome | 1 | 4 | 5 | ||
| Transmembrane transport of small molecules | 7.00E-03 | Reactome | 41 | 69 | 110 | ||
| 14 days | Signal transduction | Olfactory transduction | 1.57E-44 | KEGG | 77 | 72 | 149 |
| GPCR downstream signalling | 5.28E-26 | Reactome | 97 | 60 | 157 | ||
| Signalling by GPCR | 8.59E-25 | Reactome | 106 | 63 | 169 | ||
| Olfactory signalling Pathway | 6.18E-24 | Reactome | 43 | 36 | 79 | ||
| Signal Transduction | 2.50E-10 | Reactome | 143 | 82 | 225 | ||
| Odorant GPCRs | 2.51E-09 | Wikipathways | 24 | 19 | 43 | ||
| GPCR ligand binding | 5.85E-07 | Reactome | 44 | 23 | 67 | ||
| GPCRs, Class A Rhodopsin-like | 1.51E-06 | Wikipathways | 23 | 19 | 42 | ||
| GPCRs, Other | 1.80E-06 | Wikipathways | 18 | 12 | 30 | ||
| Non-odorant GPCRs | 3.08E-06 | Wikipathways | 34 | 17 | 51 | ||
| Class A/1 (Rhodopsin-like receptors) | 4.40E-04 | Reactome | 32 | 16 | 48 | ||
| G alpha (i) signalling events | 4.05E-03 | Reactome | 24 | 11 | 35 | ||
| Taste transduction | 9.95E-03 | KEGG | 8 | 4 | 12 | ||
| Monoamine GPCRs | 2.96E-02 | Wikipathways | 4 | 5 | 9 | ||
| G alpha (s) signalling events | 3.12E-02 | Reactome | 13 | 6 | 19 | ||
| G alpha (q) signalling events | 4.20E-02 | Reactome | 18 | 9 | 27 | ||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 4.05E-03 | Reactome | 5 | 4 | 9 | ||
| Amine ligand-binding receptors | 3.45E-02 | Reactome | 5 | 3 | 8 | ||
| Xenobiotics metabolism | Phase 1 - Functionalization of compounds | 1.60E-02 | Reactome | 3 | 16 | 19 | |
| Biological oxidations | 6.38E-03 | Reactome | 4 | 25 | 29 | ||
| Drug metabolism - other enzymes | 2.43E-02 | KEGG | 2 | 11 | 13 | ||
| Drug metabolism - cytochrome P450 | 3.12E-02 | KEGG | 3 | 14 | 17 | ||
| Cytochrome P450 - arranged by substrate type | 3.82E-02 | Reactome | 1 | 14 | 15 | ||
| Metabolism | Steroid hormone biosynthesis | 6.38E-03 | KEGG | 4 | 4 | 8 | |
| Steroid hormones | 2.73E-02 | Reactome | 3 | 10 | 13 | ||
| Retinol metabolism | 1.08E-04 | KEGG | 2 | 18 | 20 | ||
| Ascorbate and aldarate metabolism | 1.72E-03 | KEGG | 2 | 7 | 9 | ||
| Vitamin D (calciferol) metabolism | 6.67E-03 | Reactome | 1 | 3 | 4 | ||
| Metabolism of steroid hormones and vitamin D | 2.73E-02 | Reactome | 4 | 4 | 8 | ||
| Cancer signalling | Chemical carcinogenesis | 1.78E-02 | KEGG | 4 | 14 | 18 | |
| Digestive system | Recycling of bile acids and salts | 4.98E-03 | Reactome | 2 | 5 | 7 | |
| Fatty acid degradation | 1.98E-02 | KEGG | 1 | 12 | 13 | ||
| Linoleic acid metabolism | 2.96E-02 | KEGG | 3 | 9 | 11 | ||
| Bile secretion | 3.45E-02 | KEGG | 3 | 13 | 16 | ||
| Fatty acids | 3.86E-02 | Reactome | 0 | 6 | 6 | ||
| Transport of molecules | Transmembrane transport of small molecules | 4.20E-03 | Reactome | 35 | 41 | 76 | |
| SLC-mediated transmembrane transport | 3.12E-02 | Reactome | 15 | 26 | 41 | ||
| Transport of vitamins, nucleosides, and related molecules | 3.45E-02 | Reactome | 4 | 6 | 10 | ||
| Neuronal response | Neuroactive ligand-receptor interaction | 4.55E-06 | KEGG | 28 | 24 | 52 | |
| Serotonin receptors | 4.37E-02 | Reactome | 3 | 1 | 4 | ||
| 21 days | Signal transduction | Olfactory transduction | 3.02E-02 | KEGG | 29 | 5 | 34 |
| G Protein signalling Pathways | 4.31E-02 | Wikipathways | 13 | 0 | 13 | ||
| Immune response | Cell adhesion molecules (CAMs) | 8.19E-04 | KEGG | 22 | 0 | 22 | |
| Innate Immune System | 4.75E-03 | Reactome | 41 | 0 | 41 | ||
| Immune System | 5.76E-03 | Reactome | 63 | 0 | 63 | ||
| Extracellular matrix | Extracellular matrix organization | 1.51E-02 | Reactome | 23 | 0 | 23 | |
| Regulation of actin cytoskeleton | 3.53E-02 | KEGG | 21 | 0 | 21 | ||
| Neuronal response | Neuronal System | 5.76E-03 | Reactome | 24 | 1 | 25 | |
| Transmission across Chemical Synapses | 1.50E-02 | Reactome | 18 | 1 | 19 | ||
| Serotonin and anxiety-related events | 2.73E-02 | Wikipathways | 4 | 0 | 4 | ||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | 4.31E-02 | Reactome | 14 | 0 | 14 | ||
| HCN channels | 3.02E-02 | Reactome | 3 | 0 | 3 |
Pathways related to the DEG after ORA with ConsensusPathDB. The pathways were grouped per biological function. The q-value is obtained after correction of the p-values for multiple testing using the false discovery rate method.
Figure 2Visualisation of genes and pathways affected after E171 exposure. (A) Up and down regulation of expression of genes; (B) percent of group of pathways derived from the over-representation analysis (ORA) from colon tissue of mice treated with AOM/DSS and exposed to E171 during 2, 7, 14 and 21 days.
Figure 3Results of STEM analysis. Analysis performed with all the genes passing the pre-processing. Directionality changes when the maximum unit change in model profiles is between time points is higher than 2. Significant profiles are represented in colour. Similar colours represent the same type of expression profile. The number on the top left corner corresponds to the number of profile. The number at the bottom left corresponds to the associated p-value.
Figure 4Visualisation the interaction between the different biological processes (circles) regulated after exposure to E171 (octagon) for 2, 7, 14 and 21 days. Network created with Cytoscape. Only seen in the CRC mouse model in combination with E171 are in red, the ones only seen in the mice solely exposed to E171 are in blue[16], and the ones in common between the previous 2 exposures are in blue and red.
Figure 5Scheme of exposure of experimental mouse model. BALB/c mice (n = 32) were randomly distributed in 2 groups (16 per group) and were kept one week under acclimation conditions. Both the control and exposure group received a single intraperitoneal injection 12.5 mg/kg of AOM a week before the start of the experiment and DSS 2% dissolved in water ad libitum between day 1 and 5 respectively (light grey line). From day 1 to 21, E171 group received 5 mg/kg body weight by oral gavage of E171 dispersed in water 5 days per week (black line). The control group kept on receiving a vehicle (sterile water). *2 males and 2 females were sampled.